TipRanks on MSN

Akeso’s Phase II Study on AK104: A Potential Game-Changer for Vulvar Cancer Treatment

Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Akeso, Inc. is conducting a multicenter, open-label, Phase II study ...
Healio

VIDEO: New concurrent treatment shows benefit in vulvar cancer

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from a single-arm phase 2 study of the ...